Bio Pharma Dive
NOVEMBER 15, 2023
Since halting work on a sickle cell treatment early this year, Graphite Bio has laid off staff, shed assets and, now, agreed to be subsumed via a merger with Lenz Therapeutics.
Pharmaceutical Technology
NOVEMBER 15, 2023
Chief executive Amanda Pritchard says vaccination and screening could make eliminating cervical cancer a reality in the next two decades.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
NOVEMBER 15, 2023
The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027.
Pharmaceutical Technology
NOVEMBER 15, 2023
The company has struggled this year on the back of reduced Covid-19 medication sales and is now streamlining costs.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 15, 2023
Timing is everything. For early risers and late-nighters alike, listening to your internal clock may be the key to success. From the classroom to the courtroom and beyond, people perform best on challenging tasks at a time of day that aligns with their circadian rhythm.
Bio Pharma Dive
NOVEMBER 15, 2023
Now independent Mural Oncology will focus on advancing a pipeline of engineered cytokines for cancer, while Alkermes has recast itself as a “pure-play” neuroscience company.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 15, 2023
The National Institute of Mental Health and Neuro Sciences (NIMHANS) in partnership with the University of Liverpool along with a £1.5 million fund support from Pratiksha Trust, will now accelerate the pace of research in mental health & neurosciences. This includes Japanese Encephalitis which requires early detection and neurocysticercosis, another serious brain infection.
Pharmaceutical Technology
NOVEMBER 15, 2023
The UK JCVI has recommended the addition of chickenpox vaccine to the country's routine immunisation programme for children.
Fierce Pharma
NOVEMBER 15, 2023
In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival. | In response to an onslaught from Eli Lilly, Novo Nordisk is escalating the obesity market battle with a new head-to-head trial against its archrival.
Pharmaceutical Technology
NOVEMBER 15, 2023
The use of validated methods for sterilising primary packaging before aseptic fill-and-finish plays a critical role in patient safety.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
NOVEMBER 15, 2023
The U.K.’s Medicines and Healthcare products Regulatory Agency on Thursday provided conditional marketing authorization for Vertex Pharmaceuticals and CRISPR Therapeutics’ gene-edited therapy exa-cel.
Pharmaceutical Technology
NOVEMBER 15, 2023
T-Therapeutics plans to use the Series A funds to develop T-cell therapies for cancer and auto-immune disorders.
Fierce Pharma
NOVEMBER 15, 2023
How popular have Novo Nordisk’s semaglutide drugs become for weight loss in Europe? | How popular have Novo Nordisk’s semaglutide drugs become for weight loss in Europe? The craze is such that Germany’s drug regulator is considering banning the export of Ozempic, according to a report in Der Spiegel magazine.
Pharmaceutical Technology
NOVEMBER 15, 2023
Atreca has made significant cuts to its workforce (by 40%) for the second consecutive quarter in 2023 in an effort to cut costs.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharma Times
NOVEMBER 15, 2023
CHD is a common birth defect that affects the development of the heart and brain - News - PharmaTimes
Pharmaceutical Technology
NOVEMBER 15, 2023
The liquid suspension requires no preparation or refrigeration and treats bacterial infections such as rosacea and pelvic inflammatory disease.
Fierce Pharma
NOVEMBER 15, 2023
If you’re curious about the pitfalls of CAR-T drug commercialization, look no further than Bristol Myers Squibb’s Abecma partner 2seventy bio. | After reporting a sizable revenue decline for its BMS-parntered multiple myeloma cell therapy in 2023’s third quarter, 2seventy stands out as a prime example of the dangers of scaling up a process before suffering lower-than-expected demand, one group of analysts contends.
Pharmaceutical Technology
NOVEMBER 15, 2023
Almirall has entered into a collaboration with Absci for the development and commercialisation of new treatments for dermatological ailments.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioSpace
NOVEMBER 15, 2023
The Japanese pharma contends that an analysis of the four deaths in its AT132 gene therapy clinical trial shows it is still viable as a potential treatment for a fatal, rare genetic disease.
Pharmaceutical Technology
NOVEMBER 15, 2023
Is the pharmaceutical industry prepared to phase out HFAs used in pressurised metered-dose inhalers (pMDI) for the treatment of asthma?
XTalks
NOVEMBER 15, 2023
Starry soda, Pepsi’s innovative entry in the lemon-lime soda market, has nearly completed its first year on the market. Introduced in January 2023, this strategic move was aimed at competing with Sprite, Coca-Cola’s dominant lemon-lime beverage, which boasts a seven percent share in the $82 billion US soda market. Sierra Mist, Pepsi’s previous contender, only managed to secure about 0.1 percent of this market share.
Pharmaceutical Technology
NOVEMBER 15, 2023
Despite negotiations being ongoing since COP27, they have been slowed down by a lot of disagreements on how the fund will work.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Fierce Pharma
NOVEMBER 15, 2023
CorMedix went through a lot to secure its FDA approval for DefenCath. | CorMedix went through a lot to secure its FDA approval for DefenCath. There was a reorganization, a CEO change, an exit from Europe, two complete response letters and a switch of manufacturers and suppliers. And it took a novel pathway for the approval to finally come through on Wednesday.
Pharmaceutical Technology
NOVEMBER 15, 2023
Autifony Therapeutics and Jazz Pharmaceuticals have signed a $770.5m deal for the discovery and development of drug candidates.
BioSpace
NOVEMBER 15, 2023
After Bristol Myers Squibb picked up Augtyro as part of its $4.1 billion takeover of Turning Point Therapeutics last year, the ROS1-positive non-small cell lung cancer drug reached the regulatory finish line on Wednesday.
Pharmaceutical Technology
NOVEMBER 15, 2023
At BIO-Europe 2023, experts highlighted challenges in fundraising and concerns about impending EU legislative changes.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Reporter
NOVEMBER 15, 2023
Weight loss drugs known as GLP-1s have caused a stir among patients and investors, with many CDMOs now looking to tap into the booming market.
BioSpace
NOVEMBER 15, 2023
Just a week after it secured FDA approval, Eli Lilly’s Zepbound now faces a challenge from Novo Nordisk’s investigational next-generation weight-loss candidate CagriSema in a Phase III trial.
Pharma Times
NOVEMBER 15, 2023
Both programmes will be offered to those most at risk of developing STIs - News - PharmaTimes
Drug Channels
NOVEMBER 15, 2023
In Medicare Part D in 2024: The Seven Largest Companies' Preferred Pharmacy Networks and the Coming Collapse of the PDP Market , I documented how those networks now dominate stand-alone Medicare Part D prescription drug plans (PDPs) and have become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the seven largest retail chains’ participation in the 20 major 2024 Part D networks that the eight largest plan sponsors will offer.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
264 
Let's personalize your content